E-viri
Recenzirano
-
Hsieh, Chih-Chia; Lee, Chung-Hsun; Li, Ming-Chi; Hong, Ming-Yuan; Chi, Chih-Hsien; Lee, Ching-Chi
International journal of antimicrobial agents, 04/2016, Letnik: 47, Številka: 4Journal Article
Highlights • Third-generation cephalosporins (3GCs) cefotaxime (CTX) and ceftriaxone (CRO) are commonly prescribed for the treatment of community-onset bacteraemia. Since January 2010, the CLSI susceptibility breakpoints for CTX and CRO were lowered from an MIC of ≤8 mg/L to ≤1 mg/L. • Clinical evidence supporting the updated interpretive breakpoint is limited. • Focusing on patients with community-onset Enterobacteriaceae bacteraemia who received empirical 3GC therapy, the present study provides clinically critical evidence to validate the proposed reduction in the CTX breakpoint.
